Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

964279

	registered interest
	date	03/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	General Practitioners
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps his Department is taking to ensure that (a) Brighton and Hove and (b) other similar cities in England have an adequate number of GP surgeries.
	tabling member constituency	Brighton, Kemptown
	tabling member printed	Lloyd Russell-Moyle
	uin	169714
	answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>The General Practice Forward View (GP Forward View), published in April 2016, commits to increasing investment in General Practice by £2.4 billion a year by 2020/21 from £9.7 billion in 2015/16 to over £12 billion by 2020/21 – a 14% real-terms increase. This investment will improve patient care and access, and facilitate new ways of providing primary care.</p><p> </p><p>Commissioners of primary medical care services monitor practice catchment areas to ensure that all areas of the country have primary medical care cover, and through an annual review of every primary medical care contract are aware of local primary medical care capacity and how this meets demand.</p><p> </p><p>Practices are funded on a weighted population basis and therefore, where populations grow gradually, practices receive additional investment to take on new patients which allows them to grow to maintain services for patients. There has been a national trend in practices becoming larger, employing more staff and operating with a more diverse workforce in order to meet rising demand.</p><p> </p><p>Brighton and Hove Clinical Commissioning Group (CCG) is investing in general practice to improve patients’ access to GP services and increase the range of services to help support patients manage their conditions. Measures include financial and educational support to help GPs run their surgeries more effectively and efficiently.</p><p> </p><p>A key part of local plans to improve health and social care across the city is to make general practice more sustainable, more resilient and ensure it works efficiently and effectively for many years ahead. This will include integrating some services with other clinical specialists, for example pharmacists better supporting GPs, and helping GPs work more collaboratively. There are also a number of specific schemes in place as part of the CCG’s workforce strategy including the GP retention package and overseas recruitment.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/09/2018 16:19:24 answering member 4067 label Biography information for Steve Brine
	tabling member	4615 label Biography information for Lloyd Russell-Moyle

963992

	registered interest
	date	03/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Alcoholic Drinks: Misuse
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to page 28 of the Government's 2017 Drug Strategy, published in July 2017, what assessment his Department has made of the (a) potential benefits and disbenefits of the proposals to use locally retained business rates for the funding of alcohol treatment services and (b) effect of those proposals on the provision of such services in deprived areas.
	tabling member constituency	Bermondsey and Old Southwark
	tabling member printed	Neil Coyle
	uin	169387
	answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>It is for individual local authorities to decide what resources to commit to different public health services, including alcohol treatment services, to meet the needs of their local populations.</p><p> </p><p>Under the current system of 50% retained business rates, local authorities that receive more in business rates income than their baseline funding level contribute through a tariff, which is used to top up local authorities that receive less business rates income than their baseline funding level.</p><p> </p><p>The Government has been clear that under any future system there will continue to be redistribution of business rates between local authorities to take account of their relative needs.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/09/2018 16:11:00 answering member 4067 label Biography information for Steve Brine
	tabling member	4368 label Biography information for Neil Coyle

964319

	registered interest
	date	03/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Patients: Transport
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, which body is responsible for setting the criteria on who is eligible for the transport of patients to health facilities.
	tabling member constituency	Stroud
	tabling member printed	Dr David Drew
	uin	168958
	answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>Patient Transport Services (PTS) are commissioned and assessed locally by National Health Service clinical commissioning groups, which are responsible for the delivery of effective PTS.</p><p>The document, ‘Eligibility Criteria for Patient Transport Services (2007)’, published by the Department, sets out the patient eligibility criteria for PTS.</p><p>Data regarding complaints made about local PTS are not collected centrally.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 168956 168957 question first answered 11/09/2018 14:26:31 answering member 4067 label Biography information for Steve Brine
	tabling member	252 label Biography information for Dr David Drew

964895

	registered interest
	date	03/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Diseases
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether the (a) number of people with a blood-borne virus and (b) level of access to (i) screening and (ii) treatment is monitored nationally and locally.
	tabling member constituency	Leicester South
	tabling member printed	Jonathan Ashworth
	uin	169368
	answer	answer is ministerial correction date of answer 06/09/2018 answer text <p>Data are not collected for all blood borne viruses (BBV). However, Public Health England collects data on the number of people with Hepatitis A, B, C, D and E, Human T-cell virus, and HIV infections in England at national and local level. This includes monitoring universal BBV screening programmes in pregnant women and blood donors.</p><p> </p><p>Where available, both national and local data on BBV testing and treatment are published in annual data tables and reports. For example, HIV treatment and care is monitored by PHE through data on attendances and treatment of people attending National Health Service HIV specialist services in England. Hepatitis C treatment is monitored through a NHS England national treatment registry.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 06/09/2018 11:33:34 answering member 4067 label Biography information for Steve Brine
	tabling member	4244 label Biography information for Jonathan Ashworth

964091

	registered interest
	date	03/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health Services: Developing Countries
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether his Department has plans to promote universal healthcare coverage at the 73rd Session of the UN General Assembly.
	tabling member constituency	West Lancashire
	tabling member printed	Rosie Cooper
	uin	169187
	answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>The Department of Health and Social Care (DHSC) works closely with the Department for International Development (DFID) engaging regularly and at all levels to promote a shared agenda on the importance of achieving universal health coverage. We take a “one HMG” approach on all aspects of global health. This includes through international fora such as the World Health Organization (WHO), where DHSC leads the United Kingdom relationship, working in partnership with DFID and others; including sending joint delegations to WHO meetings.</p><p> </p><p>Achieving Global Goal 3 by 2030, including universal health coverage (UHC), is a priority for the UK. At the World Health Assembly this year, the former Secretary of State for Health and Social Care (the Rt. hon. Jeremy Hunt MP) stressed the importance of universal access to basic healthcare in the UK National Address. We also supported the agreement of WHO’s thirteenth General Programme of Work, with its strong focus on UHC. Preparations for the United Nations (UN) high-level meeting on UHC at the UN General Assembly in 2019 are still at an early stage but DHSC is engaging closely in the work led by DFID to identify clear deliverables that will enhance greater collective action to achieve UHC. We are working with DFID to ensure that UHC, and the steps to achieve it, are discussed in international fora, such as the G7 and G20, ahead of the High-Level Meeting.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 169185 169188 question first answered 11/09/2018 16:12:38 answering member 4067 label Biography information for Steve Brine
	tabling member	1538 label Biography information for Rosie Cooper

964215

	registered interest
	date	03/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pharmaceutical Price Regulation Scheme
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether he plans to meet representatives of patient organisations before the heads of agreement for the next Pharmaceutical Price Regulation Scheme is published.
	tabling member constituency	High Peak
	tabling member printed	Ruth George
	uin	169830
	answer	answer is ministerial correction date of answer 06/09/2018 answer text <p>The Government is committed to supporting the United Kingdom life sciences industry and ensuring that patients can access cost-effective innovative medicines and technologies at a price the National Health Service can afford. Discussions on the 2019 Pharmaceutical Price Regulation Scheme have been constructive and we are continuing to make progress.</p><p> </p><p>During the pre-negotiation engagement phase the Department sought views from a wide range of organisations, including bodies representing patients, which informed our objectives for this agreement. We will seek to meet again with patient charities to discuss the development of a full agreement once an outline deal is reached. Due to commercial sensitivities the Department cannot share further details until the point where a heads of agreement is reached.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 169829 question first answered 06/09/2018 10:29:59 answering member 4067 label Biography information for Steve Brine
	tabling member	4662 label Biography information for Ruth George

964316

	registered interest
	date	03/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Patients: Transport
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether he plans to make an assessment of the effectiveness of the operation of externally managed patient transport to ensure that there is no diminution of service standards; and if he will make a statement.
	tabling member constituency	Stroud
	tabling member printed	Dr David Drew
	uin	168956
	answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>Patient Transport Services (PTS) are commissioned and assessed locally by National Health Service clinical commissioning groups, which are responsible for the delivery of effective PTS.</p><p>The document, ‘Eligibility Criteria for Patient Transport Services (2007)’, published by the Department, sets out the patient eligibility criteria for PTS.</p><p>Data regarding complaints made about local PTS are not collected centrally.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 168957 168958 question first answered 11/09/2018 14:26:31 answering member 4067 label Biography information for Steve Brine
	tabling member	252 label Biography information for Dr David Drew

964507

	registered interest
	date	03/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Clinical Priorities Advisory Group
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether NHS England plans to share with manufacturers the cover sheets of the policy propositions sent to the Clinical Priorities Advisory Group for review in the May 2018 relative prioritisation round.
	tabling member constituency	Alyn and Deeside
	tabling member printed	Mark Tami
	uin	169113
	answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>The level of funding for products undergoing review by NHS England will be determined during the 2019/20 planning process.</p><p> </p><p>In 2016/17 and 2017/18, £25 million was set aside for discretionary investment in new specialised services. This was determined by NHS England, who considered it an appropriate level of investment in the context of NHS England’s Specialised Commissioning functioning having to achieve overall efficiency savings of approximately 2.5% and 2.7% in 2016/17 and 2017/18 respectively in order to meet the financial pressures resulting from demographic growth and the legal requirement to fund all positive National Institute for Health and Care Excellence technology appraisals.</p><p> </p><p>The split in the overall funding available between the November and May prioritisation rounds is not fixed but determined each year based on the number and estimated cost of treatments being considered by the independently chaired Clinical Priorities Advisory Group (CPAG) in each round. Revealing the split risks revealing commercial in confidence information around pricing. Anything that is not prioritised in the November round has the opportunity to be considered at the May round therefore ensuring consideration against the full funding envelope for the financial year.</p><p> </p><p>Where manufacturers have requested the cover sheets of the policy propositions, they have received the CPAG summary report as presented at the May 2018 meeting from NHS England.</p><p> </p><p>The full scoring methodology that is used at all prioritisation meetings is published on the NHS England website. This can be found at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/06/prioritisation-method-cons-response.pdf" target="_blank">https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/06/prioritisation-method-cons-response.pdf</a></p><p> </p><p>The outcome of the May 2018 prioritisation process through use of this methodology has been published as a ranked list of five prioritisation Levels. This can be found at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/2017/12/nhs-england-announces-new-specialised-treatments-for-patients/" target="_blank">https://www.england.nhs.uk/2017/12/nhs-england-announces-new-specialised-treatments-for-patients/</a></p><p> </p><p>The impact assessments for all the treatments include a narrative about the estimated forecast financial implications for each item, based on the list price. These are published as part of the public consultation pack. The detailed costings are not shared as in many cases these are based on discount prices provided on a commercial in confidence basis.</p><p> </p><p>The methodology for relative prioritisation has been subject to legal advice as part of its development and implementation, and NHS England believes it complies with equalities legislation, the NHS Constitution and human rights legislation.</p><p> </p><p>NHS England routinely publishes the stakeholder engagement response report as part of consultation through policy development, but does not routinely publish any responses that arise as a result of public consultation.</p><p> </p><p>NHS England has no plans to introduce a revised decision-making process for ultra-orphan medicines as introduced in Scotland following the Montgomery Review. NHS England will continue to use the methodology for prioritisation that has previously been publicly consulted on.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 169109 169110 169111 169112 169114 169115 169116 169117 169118 question first answered 11/09/2018 16:26:11 answering member 4067 label Biography information for Steve Brine
	tabling member	1383 label Biography information for Mark Tami

964650

	registered interest
	date	03/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medical Treatments: Innovation
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when the accelerated access pathway is planned to begin designating breakthrough products.
	tabling member constituency	Stafford
	tabling member printed	Jeremy Lefroy
	uin	169361
	answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>The Accelerated Access Collaborative will meet this autumn to launch the Accelerated Access Pathway and the first group of products will be part of their discussions.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/09/2018 14:35:39 answering member 4067 label Biography information for Steve Brine
	tabling member	4109 label Biography information for Jeremy Lefroy

964505

	registered interest
	date	03/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when the (a) Clinical Priorities Advisory Group and (b) the Specialised Services Commissioning Committee plan to meet to discuss the next round of products for consideration by the relative prioritisation process.
	tabling member constituency	Alyn and Deeside
	tabling member printed	Mark Tami
	uin	169111
	answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>The level of funding for products undergoing review by NHS England will be determined during the 2019/20 planning process.</p><p> </p><p>In 2016/17 and 2017/18, £25 million was set aside for discretionary investment in new specialised services. This was determined by NHS England, who considered it an appropriate level of investment in the context of NHS England’s Specialised Commissioning functioning having to achieve overall efficiency savings of approximately 2.5% and 2.7% in 2016/17 and 2017/18 respectively in order to meet the financial pressures resulting from demographic growth and the legal requirement to fund all positive National Institute for Health and Care Excellence technology appraisals.</p><p> </p><p>The split in the overall funding available between the November and May prioritisation rounds is not fixed but determined each year based on the number and estimated cost of treatments being considered by the independently chaired Clinical Priorities Advisory Group (CPAG) in each round. Revealing the split risks revealing commercial in confidence information around pricing. Anything that is not prioritised in the November round has the opportunity to be considered at the May round therefore ensuring consideration against the full funding envelope for the financial year.</p><p> </p><p>Where manufacturers have requested the cover sheets of the policy propositions, they have received the CPAG summary report as presented at the May 2018 meeting from NHS England.</p><p> </p><p>The full scoring methodology that is used at all prioritisation meetings is published on the NHS England website. This can be found at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/06/prioritisation-method-cons-response.pdf" target="_blank">https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/06/prioritisation-method-cons-response.pdf</a></p><p> </p><p>The outcome of the May 2018 prioritisation process through use of this methodology has been published as a ranked list of five prioritisation Levels. This can be found at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/2017/12/nhs-england-announces-new-specialised-treatments-for-patients/" target="_blank">https://www.england.nhs.uk/2017/12/nhs-england-announces-new-specialised-treatments-for-patients/</a></p><p> </p><p>The impact assessments for all the treatments include a narrative about the estimated forecast financial implications for each item, based on the list price. These are published as part of the public consultation pack. The detailed costings are not shared as in many cases these are based on discount prices provided on a commercial in confidence basis.</p><p> </p><p>The methodology for relative prioritisation has been subject to legal advice as part of its development and implementation, and NHS England believes it complies with equalities legislation, the NHS Constitution and human rights legislation.</p><p> </p><p>NHS England routinely publishes the stakeholder engagement response report as part of consultation through policy development, but does not routinely publish any responses that arise as a result of public consultation.</p><p> </p><p>NHS England has no plans to introduce a revised decision-making process for ultra-orphan medicines as introduced in Scotland following the Montgomery Review. NHS England will continue to use the methodology for prioritisation that has previously been publicly consulted on.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 169109 169110 169112 169113 169114 169115 169116 169117 169118 question first answered 11/09/2018 16:26:10 answering member 4067 label Biography information for Steve Brine
	tabling member	1383 label Biography information for Mark Tami